Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...
Innoblative Designs, Inc. (Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced today that it has received Category III Current ...
Telix Pharmaceuticals reports positive Phase 3 safety results for its investigational prostate cancer therapy, TLX591-Tx. The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results ...
Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...
LIFESTYLE NEWS - There is more to long-term health than keeping fit and eating right. Two oncologists are urging the public to become more aware of lesser known ways to reduce the risk of common ...
MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...
SHERBET, an individual patient data post hoc pooled analysis of 5 prospective trials, compared HDR-BT with SBRT in patients with intermediate-risk prostate cancer.
Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
Coherus Oncology (NASDAQ:CHRS) executives said the company has moved quickly through a multi-year transformation toward ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results